Curie Therapeutics Raises $75 Million Financing to Further its Mission of Transforming Cancer Care with Precision Radiopharmaceuticals
Incubated for 18 months by a founding syndicate comprised of Atlas Venture, Access Biotechnology, and RA Capital Management
CAMBRIDGE, Mass., Dec. 1, 2021 /PRNewswire/ -- Curie Therapeutics Inc. ("Curie"), a biotechnology company incubated by Atlas Ventures, Access Biotechnology and RA Capital Management, today announced a Series A investment of $75 million by its founding syndicate to continue the development of its multimodal pipeline of precision radiopharmaceuticals to a broad range of high unmet need solid tumors.
Commenting on the emergence of Curie from stealth, Dr. Simon Read, Curie Founder and Chief Executive Officer, said, "We envision a world where cancer care is transformed by precision radiopharmaceuticals and a future in which these drugs are increasingly integrated into mainstream treatment."
He added, "We founded Curie to maximize the potential of targeted radiopharmaceuticals for frank tumor ablation, as well as to harness the growing understanding of how radiobiology of targeted therapies can favorably modulate the tumor microenvironment as part of a rational sequence of care. Our team is unique. We have bought together seasoned leaders from pharmaceutical biotech R&D with radiobiology and radiochemistry experts drawn from both industry and academia. Backed by a syndicate of three of the foremost incubating venture firms, we have a pipeline underway and key radionuclide supply agreements for both alpha and beta radionuclide strategies to support our vision."
Dr. Dan Becker, Partner at Access Biotechnology and a member of Curie's Board of Directors (BoD), said "Radiopharmaceuticals are emerging as potent, safe, and commercially viable options for cancer patients. While late-stage therapeutic radiopharmaceutical pipelines are predominantly focused on metastatic castration resistant prostate cancer and neuroendocrine tumors, we see a much broader opportunity to drug a broad spectrum of targets with our high therapeutic index, precision radiopharmaceuticals."
Dr. Kevin Bitterman, Partner at Atlas Ventures and a member of Curie's BoD said, "All three syndicate members showed an early interest in the radiopharmaceutical space. We have been incubating Curie for 18 months with a focus on building a fully integrated company in which both peptidic and non-peptidic ligand R&D, radiochemistry, CMC and clinical translation can occur under one roof."
Dr. Josh Resnick, Managing Director of RA Capital Management and a member of Curie's BoD, added, "This founding team has the ligand discovery breadth, company formation experience, and radiobiology and CMC experience required to build the leading precision radiopharmaceutical company. We are delighted to co-lead the series A round with Access Biotechnology and Atlas Venture."
Curie Management and Board of Directors
Curie's management includes biotech leaders with broad experience across peptide discovery and development, radiochemistry, and in building top tier clinical stage peptide, radiopharmaceutical, and platform companies, including founder Simon Read, Ph.D. as CEO (former CSO of Ra Pharma, former Entrepreneur in Residence at Atlas Venture), Alonso Ricardo, Ph.D. as CSO (former Chief Technology Officer of Ra Pharma, former Entrepreneur in Residence at RA Capital Management), and Sandy Mong, M.D. as SVP of Business Development and Operations (former VP of Business Development and Operations of BridgeBio Pharma, former Entrepreneur in Residence at Atlas Venture). The broader team includes ligand discovery, radiopharmacology, radiochemistry talent from public and private peptide companies, radiopharmaceutical companies, as well as academia.
Curie's BoD consists of Kevin Bitterman, Ph.D. (Partner, Atlas Venture), Dan Becker, M.D., Ph.D. (Partner, Access Biotechnology), Josh Resnick, M.D. (Managing Director, RA Capital Management), and Simon Read, Ph.D. (CEO, Curie Therapeutics).
About Curie Therapeutics
Curie Therapeutics is a fully integrated, next-generation radiopharmaceuticals company focused on pioneering a new class of targeted radiopharmaceuticals that are both safe and effective. Curie's radiopharmaceuticals are composed of rationally designed conjugates against carefully selected biological targets, to deliver alpha and beta-emitting radionuclide payloads. Curie's mission is to revolutionize the use of radiomedicines in cancer. Learn more at www.curietherapeutics.com
About Atlas Venture
Atlas Venture is a leading biotech venture capital firm. With the goal of doing well by doing good, we have been building breakthrough biotech startups since 1993. We work side by side with exceptional scientists and entrepreneurs to translate high-impact science into medicines for patients. Our seed-led venture creation strategy rigorously selects and focuses investment on the most compelling opportunities to build scalable businesses and realize value.
For more information, please visit www.atlasventure.com.
About Access Biotechnology
About RA Capital Management
RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to provide seed funding to startups and to lead private, IPO, and follow-on financings for its portfolio companies, allowing management teams to drive value creation from inception through commercialization.
View original content to download multimedia:https://www.prnewswire.com/news-releases/curie-therapeutics-raises-75-million-financing-to-further-its-mission-of-transforming-cancer-care-with-precision-radiopharmaceuticals-301434583.html
SOURCE Curie Therapeutics